CONMED Earnings Call Transcripts
Fiscal Year 2026
-
Management highlighted accelerated growth driven by strong performance in minimally invasive surgery and sports medicine, with AirSeal, BioBrace, and Buffalo Filter as key growth drivers. International expansion, margin improvement, and ongoing investment in sales and R&D support the outlook, while tuck-in M&A remains a strategic priority.
-
Q2 2026 saw 6% organic sales growth, strong EPS, and margin expansion, driven by AirSeal, Buffalo Filter, and BioBrace. Guidance for 2026 was raised for EPS but narrowed for sales growth, with continued operational and leadership enhancements.
-
The meeting confirmed proper notice and quorum, recognized a retiring Board member, and presented three proposals: Director elections, executive compensation, and auditor ratification. All proposals passed by majority vote, with final results to be filed on Form 8-K.
-
Q1 2026 saw organic sales growth and margin improvement, driven by orthopedics and key platforms, despite a GI product line exit and higher interest expense. Full-year guidance was raised for organic growth, with EPS guidance maintained.
-
Management outlined a focused strategy on high-growth platforms—AirSeal, Buffalo Filter, and BioBrace—while exiting the GI business to optimize the portfolio. 2026 guidance reflects steady revenue and EPS, with share repurchases replacing dividends and ongoing supply chain improvements supporting growth.
Fiscal Year 2025
-
Fourth quarter sales grew 7.9% year-over-year, led by strong orthopedic and international performance, while adjusted EPS rose 6.7%. The company exited its GI product lines to focus on high-growth platforms, improved supply chain, and authorized a $150M share repurchase.
-
Q3 2025 saw 6.7% sales growth and 2.9% higher adjusted EPS, led by General Surgery and Orthopedics. Strategic review is underway, the dividend was suspended in favor of a $150M share repurchase program, and guidance for full-year revenue and EPS was narrowed.
-
Q2 2025 saw 3.1% sales growth and 17.3% higher adjusted EPS, led by strong general surgery and innovation in key product lines. Guidance for full-year revenue and EPS was raised, with supply chain improvements and legislative tailwinds supporting future growth.
-
Q1 2025 saw 3.8% constant currency sales growth, with strong gains in Foot & Ankle, BioBrace, and AirSeal. Adjusted net income and EPS rose over 19% year-over-year. Full-year guidance was raised for revenue and EPS, with tariff impacts mostly in Q4.
-
A new CEO outlined a vision focused on long-term growth, operational improvement, and innovation in large, high-margin markets. Double-digit growth is expected in key platforms, with margin expansion and M&A flexibility anticipated as leverage declines.
Fiscal Year 2024
-
Q4 and full-year 2024 saw solid sales and margin growth, with adjusted EPS up 21% year-over-year. 2025 guidance calls for 4–6% constant currency revenue growth and adjusted EPS of $4.25–$4.40, excluding potential tariff impacts. Operational improvements and supply chain fixes remain a top priority.
-
Leadership transition emphasizes growth and continuity, with a focus on simplifying the business narrative. AirSeal, Buffalo Filter, and BioBrace drive strong growth, supported by expanding markets and clinical data. Operational improvements and flexible capital allocation support ongoing margin and earnings growth.
-
Leadership transition will focus on listening and maintaining growth. M&A remains disciplined, with acquisitions driven by strategic fit, not leverage ratios. AirSeal and Buffalo Filter businesses show strong growth potential, while orthopedics and BioBrace are set for recovery and expansion. Margins and EPS are expected to improve as growth assets scale.
-
Leadership transition is underway as the CEO retires, with the business focused on minimally invasive growth platforms and resolving recent supply chain challenges. Product innovation, especially in AirSeal and BioBrace, is driving market expansion, while financials show resilience and a return to growth is expected.
-
Q3 sales grew 4.3% year-over-year, with strong U.S. and orthopedic performance, but hurricanes and IV fluid shortages impacted operations and deferred procedures. Adjusted EPS rose 16.7%, and full-year guidance was updated to reflect recent disruptions.
-
Orthopedic supply issues are expected to resolve by year-end, with no lasting market share loss. AirSeal and Buffalo Filter show strong growth potential, supported by legislative trends and clinical benefits. Financial targets include a return to high single-digit growth and margin expansion, with innovation in BioBrace and foot and ankle segments driving future performance.
-
Surgical procedure volumes remain stable, with supply chain issues in orthopedics expected to resolve by year-end. AirSeal maintains strong market differentiation and usage, while margin expansion continues, though the 60% target may be delayed. BioBrace and new product launches are progressing well, and leverage is trending down.
-
Q2 2024 saw record sales and strong EPS growth, but ongoing supply chain issues in orthopedics led to a downward revision of full-year guidance. General Surgery performed well, and gross margins improved, with management expecting operational recovery and margin gains by year-end.
-
Management targets low double-digit organic growth, supported by strong assets like AirSeal, Buffalo Filter, BioBrace, and foot & ankle. AirSeal remains resilient despite new competition, while legislative and clinical tailwinds drive Buffalo Filter and BioBrace. Margin expansion and EPS accretion from recent deals are on track.